Management of Graves' hyperthyroidism and orbitopathy in time of COVID-19 pandemic.
作者信息
Bartalena L, Chiovato L, Marcocci C, Vitti P, Piantanida E, Tanda M L
机构信息
Endocrine Unit, Department of Medicine and Surgery, University of Insubria, ASST dei Sette Laghi, Viale Borri, 57, 21100, Varese, Italy.
Unit of Internal Medicine and Endocrinology, Laboratory for Endocrine Disruptors, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
出版信息
J Endocrinol Invest. 2020 Aug;43(8):1149-1151. doi: 10.1007/s40618-020-01293-7. Epub 2020 May 21.
Abstract
摘要
相似文献
1
Management of Graves' hyperthyroidism and orbitopathy in time of COVID-19 pandemic.2019冠状病毒病大流行期间格雷夫斯病甲亢和眼眶病的管理
J Endocrinol Invest. 2020 Aug;43(8):1149-1151. doi: 10.1007/s40618-020-01293-7. Epub 2020 May 21.
2
The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy.Graves 病伴发眼眶病患者中如何治疗格雷夫斯甲亢的困境。
J Clin Endocrinol Metab. 2011 Mar;96(3):592-9. doi: 10.1210/jc.2010-2329. Epub 2010 Dec 29.
3
Graves' Disease.格雷夫斯病
N Engl J Med. 2016 Oct 20;375(16):1552-1565. doi: 10.1056/NEJMra1510030.
4
Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy.Graves 病伴 Graves 眼病甲状腺功能亢进症患者长期抗甲状腺药物治疗的转归。
Thyroid. 2011 Mar;21(3):279-83. doi: 10.1089/thy.2010.0181. Epub 2010 Dec 29.
5
Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid?近期发病的格雷夫斯甲亢和格雷夫斯眼眶病：是否对甲状腺进行消融治疗？
J Endocrinol Invest. 2008 Jun;31(6):578-81. doi: 10.1007/BF03346411.
6
Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.严重 Graves 眼病患者长期低剂量抗甲状腺药物治疗期间 Graves 甲亢的持续控制。
Thyroid. 2011 Sep;21(9):951-6. doi: 10.1089/thy.2011.0039. Epub 2011 Aug 11.
7
Asymmetric Graves' Orbitopathy.非对称格雷夫斯眼病。
Front Endocrinol (Lausanne). 2020 Dec 17;11:611845. doi: 10.3389/fendo.2020.611845. eCollection 2020.
8
Childhood Graves' ophthalmopathy: results of a European questionnaire study.儿童格雷夫斯眼病：一项欧洲问卷调查研究的结果
Eur J Endocrinol. 2005 Oct;153(4):515-21. doi: 10.1530/eje.1.01991.
9
Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement.格雷夫斯病甲亢治疗方式对格雷夫斯眼眶病的影响：2015年意大利内分泌学会共识声明
J Endocrinol Invest. 2015 Apr;38(4):481-7. doi: 10.1007/s40618-015-0257-z. Epub 2015 Feb 27.
10
[Graves' ophthalmopathy from the internist's perspective].[从内科医生角度看格雷夫斯眼病]
Ophthalmologe. 2011 May;108(5):410-6. doi: 10.1007/s00347-010-2185-9.
引用本文的文献
1
The effect of COVID-19 process on patients with endocrinological disease in a pandemic hospital: What happened to the others?大流行医院中 COVID-19 病程对内分泌疾病患者的影响：其他人发生了什么？
Arch Endocrinol Metab. 2023 Jan 18;67(1):45-54. doi: 10.20945/2359-3997000000525. Epub 2022 Oct 11.
2
Potential relationships between COVID-19 and the thyroid gland: an update.COVID-19 与甲状腺之间潜在的关系：最新进展。
J Int Med Res. 2022 Feb;50(2):3000605221082898. doi: 10.1177/03000605221082898.
3
SARS-CoV-2: Emerging Role in the Pathogenesis of Various Thyroid Diseases.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）：在各种甲状腺疾病发病机制中的新作用
J Inflamm Res. 2021 Nov 24;14:6191-6221. doi: 10.2147/JIR.S332705. eCollection 2021.
4
Management of thyroid disorders during the COVID-19 outbreak: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM).COVID-19 疫情期间甲状腺疾病的管理：巴西内分泌学会甲状腺分会的立场声明。
Arch Endocrinol Metab. 2021 Nov 3;65(3):368-375. doi: 10.20945/2359-3997000000352. Epub 2021 Apr 12.
5
Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects.甲状腺与 COVID-19：病理生理、临床和组织方面的综述。
J Endocrinol Invest. 2021 Sep;44(9):1801-1814. doi: 10.1007/s40618-021-01554-z. Epub 2021 Mar 25.
6
Association of Other Autoimmune Diseases With Thyroid Eye Disease.其他自身免疫性疾病与甲状腺眼病的关系。
Front Endocrinol (Lausanne). 2021 Mar 5;12:644200. doi: 10.3389/fendo.2021.644200. eCollection 2021.
7
Impact of COVID-19 on the thyroid gland: an update.新型冠状病毒肺炎对甲状腺的影响：最新进展。
Rev Endocr Metab Disord. 2021 Dec;22(4):803-815. doi: 10.1007/s11154-020-09615-z. Epub 2020 Nov 25.
8
Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management.甲状腺疾病与 SARS-CoV-2 感染：从病理生理学机制到患者管理。
Ann Endocrinol (Paris). 2020 Oct;81(5):507-510. doi: 10.1016/j.ando.2020.09.001. Epub 2020 Sep 18.
9
Management of Graves Thyroidal and Extrathyroidal Disease: An Update.格雷夫斯甲状腺和甲状腺外疾病的管理：更新。
J Clin Endocrinol Metab. 2020 Dec 1;105(12):3704-20. doi: 10.1210/clinem/dgaa646.
10
Thyroid surgery during coronavirus-19 pandemic phases I, II and III: lessons learned in China, South Korea, Iran and Italy.新冠肺炎疫情流行期间的甲状腺手术：中国、韩国、伊朗和意大利的经验教训。
J Endocrinol Invest. 2021 May;44(5):1065-1073. doi: 10.1007/s40618-020-01407-1. Epub 2020 Sep 2.
本文引用的文献
1
COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency.2019冠状病毒病感染与糖皮质激素：来自意大利内分泌学会关于肾上腺功能不全激素替代治疗专家意见的更新
J Endocrinol Invest. 2020 Aug;43(8):1141-1147. doi: 10.1007/s40618-020-01266-w. Epub 2020 Apr 25.
2
An invisible hand has guided clinical endocrinology toward an unexpected future.一只无形的手已将临床内分泌学引向意想不到的未来。
J Endocrinol Invest. 2020 Jul;43(7):1037-1038. doi: 10.1007/s40618-020-01256-y. Epub 2020 Apr 20.
3
COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology.2019冠状病毒病与内分泌疾病。欧洲内分泌学会声明。
Endocrine. 2020 Apr;68(1):2-5. doi: 10.1007/s12020-020-02294-5.
4
Safety of long-term antithyroid drug treatment? A systematic review.长期抗甲状腺药物治疗的安全性？系统评价。
J Endocrinol Invest. 2019 Nov;42(11):1273-1283. doi: 10.1007/s40618-019-01054-1. Epub 2019 May 27.
5
Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study.Graves 病的主要治疗方法与心血管发病率和死亡率：一项关联记录队列研究。
Lancet Diabetes Endocrinol. 2019 Apr;7(4):278-287. doi: 10.1016/S2213-8587(19)30059-2. Epub 2019 Feb 28.
6
2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.2018年欧洲甲状腺协会格雷夫斯甲亢管理指南。
Eur Thyroid J. 2018 Aug;7(4):167-186. doi: 10.1159/000490384. Epub 2018 Jul 25.
7
Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management.抗甲状腺药物治疗 Graves 病：基于患者个体管理的治疗后复发的基线预测模型。
J Endocrinol Invest. 2018 Dec;41(12):1425-1432. doi: 10.1007/s40618-018-0918-9. Epub 2018 Jun 26.
8
Thyroid Storm: A Japanese Perspective.甲状腺危象：日本视角。
Thyroid. 2018 Jan;28(1):32-40. doi: 10.1089/thy.2017.0243. Epub 2017 Oct 5.
9
Increased risk for thionamide-induced agranulocytosis in elderly patients: a case presentation and literature review.老年患者硫代酰胺诱发粒细胞缺乏症的风险增加：病例报告与文献综述
BMJ Case Rep. 2017 Jul 17;2017:bcr-2017-220924. doi: 10.1136/bcr-2017-220924.
10
Excess Mortality in Treated and Untreated Hyperthyroidism Is Related to Cumulative Periods of Low Serum TSH.治疗和未治疗的甲状腺功能亢进症中的超额死亡率与血清促甲状腺激素水平低的累积时长有关。
J Clin Endocrinol Metab. 2017 Jul 1;102(7):2301-2309. doi: 10.1210/jc.2017-00166.
Zotero 插件